Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Enanta Pharmaceuticals ( (ENTA) ) has issued an update.
On September 30, 2025, Enanta Pharmaceuticals announced a public offering of 6,500,000 shares of its common stock at $10.00 per share, with an option for underwriters to purchase an additional 975,000 shares. The expected net proceeds of approximately $60.6 million will support the company’s operations, with the offering set to close on October 2, 2025, subject to customary conditions.
The most recent analyst rating on (ENTA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
Spark’s Take on ENTA Stock
According to Spark, TipRanks’ AI Analyst, ENTA is a Underperform.
Enanta Pharmaceuticals’ overall stock score is primarily impacted by its poor financial performance, characterized by significant losses, high leverage, and cash flow issues. Technical analysis indicates bearish momentum, while valuation metrics highlight ongoing profitability challenges. The absence of earnings call data and corporate events further limits positive influences on the score.
To see Spark’s full report on ENTA stock, click here.
More about Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of small molecule drugs for viral infections and liver diseases.
Average Trading Volume: 501,421
Technical Sentiment Signal: Buy
Current Market Cap: $324.1M
For detailed information about ENTA stock, go to TipRanks’ Stock Analysis page.